[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jade Biosciences Inc (JBIO)

Jade Biosciences Inc (JBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,324,135
  • Shares Outstanding, K 49,316
  • Annual Sales, $ 0 K
  • Annual Income, $ -127,410 K
  • EBIT $ -114 M
  • EBITDA $ -114 M
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.74

Options Overview Details

View History
  • Implied Volatility 149.83% (-1.72%)
  • Historical Volatility 73.04%
  • IV Percentile 20%
  • IV Rank 9.33%
  • IV High 692.38% on 04/29/25
  • IV Low 94.02% on 11/17/25
  • Expected Move (DTE 17) 4.42 (16.33%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 11
  • Put/Call OI Ratio 5.00
  • Today's Open Interest 1,807
  • Open Int (30-Day) 1,784
  • Expected Range 22.64 to 31.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.52
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.57
  • Prior Year $-3.16
  • Growth Rate Est. (year over year) +83.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.03 +104.14%
on 03/30/26
28.00 -4.96%
on 04/27/26
+13.22 (+98.73%)
since 03/27/26
3-Month
12.91 +106.12%
on 03/24/26
28.00 -4.96%
on 04/27/26
+10.97 (+70.14%)
since 01/28/26
52-Week
6.57 +305.33%
on 06/13/25
28.00 -4.96%
on 04/27/26
-67.19 (-71.63%)
since 04/28/25

Most Recent Stories

More News
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 27.12 (+1.01%)
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer

SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 27.12 (+1.01%)
Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated...

JBIO : 27.12 (+1.01%)
Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies...

JBIO : 27.12 (+1.01%)
Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026  Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin...

JBIO : 27.12 (+1.01%)
Jade Biosciences Announces $45 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 27.12 (+1.01%)
Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Presented favorable preclinical safety data for JADE101 and a translational analysis of APRIL mediated biomarker responses at the American Society of Nephrology Kidney Week 2025, reinforcing its potential...

JBIO : 27.12 (+1.01%)
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused...

JBIO : 27.12 (+1.01%)
Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies...

JBIO : 27.12 (+1.01%)
Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class...

JBIO : 27.12 (+1.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 80%. The market is in extreme overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 30.43
2nd Resistance Point 29.22
1st Resistance Point 28.03
Last Price 27.12
1st Support Level 25.63
2nd Support Level 24.42
3rd Support Level 23.23

See More

52-Week High 28.00
Last Price 27.12
Fibonacci 61.8% 19.81
Fibonacci 50% 17.28
Fibonacci 38.2% 14.75
52-Week Low 6.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.